- Home
- AEON vs ALLR Comparison
AEON vs ALLR Comparison
Compare AEON & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- ALLR
- Stock Information
- Founded
- AEON N/A
- ALLR 2004
- Country
- AEON United States
- ALLR United States
- Employees
- AEON N/A
- ALLR N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- AEON Health Care
- ALLR Health Care
- Exchange
- AEON Nasdaq
- ALLR Nasdaq
- Market Cap
- AEON 4.2M
- ALLR 4.0M
- IPO Year
- AEON N/A
- ALLR N/A
- Fundamental
- Price
- AEON $0.47
- ALLR $1.05
- Analyst Decision
- AEON Strong Buy
- ALLR
- Analyst Count
- AEON 1
- ALLR 0
- Target Price
- AEON $360.00
- ALLR N/A
- AVG Volume (30 Days)
- AEON 294.1K
- ALLR 1.1M
- Earning Date
- AEON 05-16-2025
- ALLR 05-20-2025
- Dividend Yield
- AEON N/A
- ALLR N/A
- EPS Growth
- AEON N/A
- ALLR N/A
- EPS
- AEON 72.93
- ALLR N/A
- Revenue
- AEON N/A
- ALLR N/A
- Revenue This Year
- AEON N/A
- ALLR N/A
- Revenue Next Year
- AEON N/A
- ALLR N/A
- P/E Ratio
- AEON $0.01
- ALLR N/A
- Revenue Growth
- AEON N/A
- ALLR N/A
- 52 Week Low
- AEON $0.38
- ALLR $0.61
- 52 Week High
- AEON $269.28
- ALLR $25.47
- Technical
- Relative Strength Index (RSI)
- AEON 33.14
- ALLR 52.91
- Support Level
- AEON $0.43
- ALLR $1.01
- Resistance Level
- AEON $0.57
- ALLR $1.10
- Average True Range (ATR)
- AEON 0.04
- ALLR 0.10
- MACD
- AEON 0.10
- ALLR -0.00
- Stochastic Oscillator
- AEON 49.95
- ALLR 35.71
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.